BioCanada

Found 34,450 articles

• Covalon Announces Second Quarter Results for Fiscal 2023

  5/25/2023

  Covalon Technologies Ltd., an advanced medical technologies company, announced its second quarter fiscal 2023 results.

• Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering

  5/25/2023

  Achieve Life Sciences, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registered direct offering.

• Microbiome Insights Launches Cutting-Edge Metatranscriptomic Sequencing Services

  5/25/2023

  Microbiome Insights Inc., a global leader in microbial sequencing and bioinformatic analysis, is pleased to announce the launch of its new metatranscriptomic sequencing services.

• Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

  5/25/2023

  Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce several recent initiatives aimed at best positioning the company for the expected FDA approval of MDMA-assisted therapy ("MDMA-AT") in the United States in the first half of 2024.

• Kane Biotech Announces FDA 510(k) Clearance for its coactiv+™ Antimicrobial Wound GelKane’s first FDA cleared medical device aims to disrupt global wound care hydrogel market

  5/25/2023

  Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its coactiv+™ Antimicrobial Wound Gel from the U.S. Food and Drug Administration (FDA) for the management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns.

• Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023

  5/25/2023

  Theratechnologies Inc. announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug conjugate candidate, sudocetaxel zendusortide, in patients with advanced solid tumors.

• Kane Biotech Announces First Quarter 2023 Financial Results

  5/25/2023

  Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, announced its first quarter 2023 financial results.

• Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

  5/25/2023

  Oncolytics Biotech® Inc. announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer.

• Aptose Enters into $25 Million Committed Equity Facility

  5/25/2023

  Aptose Biosciences Inc., a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, announced that it has entered into a common share purchase agreement and registration rights agreement with an institutional investor.

• BioSyent Declares Second Quarter 2023 Dividend

  5/25/2023

  BioSyent Inc. is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.04 per common share, payable in Canadian Dollars on June 15, 2023, to shareholders of record at the close of business on June 2, 2023.

• Therma Bright Expands U.S. Distribution of Venowave Device to Increase Sales Under Temporary CPT(R) & HCPCS Codes

  5/25/2023

  Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company is working with its U.S distributor network

• Brain Cancer Canada Grants Research Funds to Improve Survival Rates for Glioblastoma and Other Gliomas

  5/25/2023

  Brain Cancer Canada, a leading charity in the fight against brain cancer, is delighted to announce a $50,000 research grant to Dr. Amit Singnurkar at Sunnybrook Health Sciences Centre.

• Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

  5/25/2023

  Ceapro Inc.(TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

• Spectral Medical Hosts Successful Investigator Meeting; Expected to Help Bolster Enrollment ActivitiesTigris trial enrolment at 60 patients

  5/24/2023

  Spectral Medical Inc. today reported hosting an investigator meeting in Charlotte, North Carolina on May 17 - 18, 2023.

• Biorem Reports First Quarter Financial Results - May 24, 2023

  5/24/2023

  BIOREM Inc. today announced results for the three month period ended March 31, 2023.

• Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial

  5/24/2023

  Cybin Inc. today announced that the first participants have been dosed with CYB004 in its ongoing three-part Phase 1 clinical trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) and CYB004 in healthy volunteers.

• NurExone Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/24/2023

  NurExone Biologic Inc. has released its financial results for the quarter ended March 31, 2023.

• Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

  5/24/2023

  Appili Therapeutics Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1501 under the U.S. Application No. 18/072,154 filed on November 30, 2022 and titled “ Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same”.

• Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital

  5/24/2023

  Tryp Therapeutics, Inc. announced it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for its planned Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering from Irritable Bowel Syndrome at Massachusetts General Hospital.

• Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer

  5/24/2023

  Theralase® Technologies Inc. is pleased to announce that Roger DuMoulin-White, B.Sc., P.Eng., Pro. Dir. has been appointed as President and Chief Executive Officer of the Company.